Top news
FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of ...
US approves Alzheimer's drug that modestly slows disease
By Matthew Perrone
FDA approves Alzheimer's drug that slowed cognitive decline in clinical trial
By Spencer Kimball
FDA approves new antibody to slow Alzheimer's disease, even as safety concerns linger
By Jennifer Couzin
All coverage
Eisai, Biogen get U.S. FDA approval for Alzheimer's drug, apply for full approval
By Julie Steenhuysen & Deena Beasley
A new Alzheimer’s drug will cost $26,500 a year. Who will be able to get it?
By Berkeley Lovelace & Berkeley Lovelace Jr.
Most Alzheimer’s patients would pay up to $26,500 per year for new treatment Leqembi
By Spencer Kimball
Alzheimer's drug that slows cognitive decline gets FDA approval
By Laurie McGinley
New Alzheimer's Drug Approved by FDA, Promises to Slow Disease
By Joseph Walker
Alzheimer’s drug lecanemab receives accelerated approval amid safety concerns
By Jacqueline Howard & Brenda Goodman
FDA Approves Lecanemab, a New Alzheimer's Drug
By Alice Park
FDA approves new Alzheimer's drug Leqembi
By Adam Feuerstein
EXPLAINER: New drug slows Alzheimer's but comes with caveats
By Lauran Neergaard & Matthew Perrone
FDA approves new Alzheimer’s drug that appears to slow disease
By Berkeley Lovelace & Berkeley Lovelace Jr.